Omeros Reports Breakthrough Primate Study Results for Novel AML Therapeutic OncotoX-AML
核心洞察
Omeros Corporation announced successful completion of a primate study for OncotoX-AML (搜索), showing up to 99% reduction in myeloid progenitor cells that give rise to acute myeloid leukemia.
The engineered biologic demonstrated superior efficacy compared to current standard-of-care treatments, extending survival to over 100 days in xenograft models versus 8 days with venetoclax-azacitidine combination.
OncotoX-AML (搜索)'s unique mechanism works independently of genetic mutations found in 90% of AML patients and was well-tolerated without significant safety signals.
Omeros Corporation has achieved a significant milestone in acute myeloid leukemia (AML) treatment development, announcing successful completion of its initial nonhuman primate study for OncotoX-AML (搜索), an engineered biologic targeting this aggressive blood cancer. The study demonstrated marked efficacy in reducing myeloid progenitor cells by up to 99 percent with a single treatment course, while maintaining an encouraging safety profile.
Promising Efficacy and Safety Profile
The primate study revealed that OncotoX-AML (搜索) achieved the desired pharmacologic response through marked, selective, reversible, and dose-related reduction in myeloid progenitor cells—the precursor cells that can mutate and lead to AML development. Importantly, the treatment was well tolerated without causing broader or lasting hematologic changes while preserving hematopoietic stem cells.
"There were no observed safety signals or meaningful changes in blood chemistry values often seen with current AML treatments," according to the company's announcement. This safety profile represents a potential advantage over existing AML therapies, which are limited by substantial side effects.
Superior Performance Against Standard Care
In preclinical studies, OncotoX-AML (搜索) demonstrated remarkable superiority over current standard-of-care treatment. Using multiple in vivo murine-human xenograft models, the therapeutic consistently outperformed the combination of venetoclax and azacitidine (VenAza), the current AML standard-of-care.
The results were striking: OncotoX-AML (搜索) eradicated all disseminated tumors and extended survival in all animals to over 100 days without evidence of tumor recurrence. In contrast, the VenAza combination achieved only a median survival increase of 8 days across the various models tested.
Novel Mechanism of Action
OncotoX-AML (搜索) is engineered as a biologic designed to selectively kill both AML blasts (abnormal myeloid cells) and relapse-related leukemia stem cells. Its unique mechanism of action operates independently of myeloid cell genetic mutations, including TP53 (搜索), NPM1 (搜索), KMT2A (搜索), and FLT3 (搜索)—mutations collectively found in approximately 90 percent of AML patients.
In preclinical studies using patient-derived AML cells, OncotoX-AML (搜索) molecules preferentially and efficiently killed myeloid cancer cells regardless of their respective mutational signature, suggesting broad applicability across different AML subtypes.
Clinical Development Timeline
Following these encouraging results, Omeros is initiating IND-enabling studies to advance OncotoX-AML (搜索) toward clinical testing. The company is targeting a first-in-human trial for late 2027, guided by a distinguished advisory board of AML experts.
"We're excited by these data—both the efficacy results and the absence of any meaningful safety signal," stated Gregory A. Demopulos, M.D., Chairman and Chief Executive Officer of Omeros. "With the guidance of our distinguished advisory board of AML experts, we look forward to advancing OncotoX-AML (搜索) to the clinic, targeting a first-in-human trial for late 2027."
Addressing Critical Medical Need
AML represents a significant medical challenge as an aggressive and highly fatal bone marrow and blood cancer. The disease was estimated to have been responsible for over 11,000 U.S. deaths in 2025, highlighting the urgent need for more effective treatments with improved safety profiles.
Current AML treatments, including chemotherapeutics and antibody-drug conjugates, face limitations due to substantial side effects, creating an opportunity for novel therapeutics like OncotoX-AML (搜索) that may offer improved tolerability while maintaining or enhancing efficacy.